Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive sublingual immunotherapy for house dust mite sensitized preschool children
2016-002844-18Phase 3Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2016
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of house dust mite allergen extract in house dust mite allergy, allergic rhinitis (AR), asthma and 1 more, sponsored by Medical University of Vienna. Primary endpoint: Primary immunomodulatory response. Started Dec 2016; status: completed.
02
Drugs
house dust mite allergen extract
03
Conditions
house dust mite allergyallergic rhinitis (AR)asthmaAllergen sensitization
Beyond the preview
Go deeper on 2016-002844-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002844-18.